17-Nov-2025 7:00 AM CST - Business Wire ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results $NDRA #MASH--ENDRA Life Sciences Inc. (Nasdaq: NDRA) (ENDRA or the Company), a pioneer in biomarker imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease (MASLD) and metabolic dysfunction associated steatohepatitis (MASH), today provided a business update and reported financial results for the three and nine months ended September 30, 2025. Business Update Completed private placement of up to $14.4 million. On
14-Aug-2025 3:05 PM CST - Business Wire ENDRA Life Sciences Provides a Business Update and Reports Second Quarter 2025 Financial Results $NDRA #MASH--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS), today provided a business update and reported financial results for the three and six months ended June 30, 2025. Business Update Advanced development of TAEUS Liver. ENDRA advanced its product development work with enhancements to the TAEUS Liver systems probe design and proprietary algorithms, which are expected to deliver significantly improved accuracy and
15-May-2025 3:05 PM CST - Business Wire ENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial Results ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS), today provided a business update and reported financial results for the three months ended March 31, 2025. Business Update Incorporating Liver Diagnostics into the Management of Metabolic Disease ENDRA recently announced a strategic pivot to position the company to play an integral role in the treatment of metabolic disease. With a sharpened mission to transform
31-Mar-2025 7:00 AM CST - Business Wire ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS), today reported financial results for the fourth quarter and full-year ended December 31, 2024, and provided a business update. Business Update ENDRA made significant progress against many of the new initiatives discussed during the Companys August 22, 2024, conference call to advance its TAEUS Liver device along the development and regulatory process. In additi
15-Nov-2024 8:24 AM CST - Business Wire ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS), today reported financial results for the three and nine months ended September 30, 2024 and provided a business update. Highlights from the third quarter and recent weeks include: Developed data analysis features for TAEUS platform by introducing new models rooted in artificial intelligence (AI), machine learning (ML) and deep learning (DL). As part of its conti
17-Nov-2025 7:00 AM CST - Business Wire ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results $NDRA #MASH--ENDRA Life Sciences Inc. (Nasdaq: NDRA) (ENDRA or the Company), a pioneer in biomarker imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease (MASLD) and metabolic dysfunction associated steatohepatitis (MASH), today provided a business update and reported financial results for the three and nine months ended September 30, 2025. Business Update Completed private placement of up to $14.4 million. On
14-Aug-2025 3:05 PM CST - Business Wire ENDRA Life Sciences Provides a Business Update and Reports Second Quarter 2025 Financial Results $NDRA #MASH--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS), today provided a business update and reported financial results for the three and six months ended June 30, 2025. Business Update Advanced development of TAEUS Liver. ENDRA advanced its product development work with enhancements to the TAEUS Liver systems probe design and proprietary algorithms, which are expected to deliver significantly improved accuracy and
15-May-2025 3:05 PM CST - Business Wire ENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial Results ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS), today provided a business update and reported financial results for the three months ended March 31, 2025. Business Update Incorporating Liver Diagnostics into the Management of Metabolic Disease ENDRA recently announced a strategic pivot to position the company to play an integral role in the treatment of metabolic disease. With a sharpened mission to transform
31-Mar-2025 7:00 AM CST - Business Wire ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS), today reported financial results for the fourth quarter and full-year ended December 31, 2024, and provided a business update. Business Update ENDRA made significant progress against many of the new initiatives discussed during the Companys August 22, 2024, conference call to advance its TAEUS Liver device along the development and regulatory process. In additi
15-Nov-2024 8:24 AM CST - Business Wire ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS), today reported financial results for the three and nine months ended September 30, 2024 and provided a business update. Highlights from the third quarter and recent weeks include: Developed data analysis features for TAEUS platform by introducing new models rooted in artificial intelligence (AI), machine learning (ML) and deep learning (DL). As part of its conti
